Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cue Biopharma
Cancer biotech
Biotech
Cue chalks up phase 2 hives win for Xolair challenger
A midstage study of Cue Biopharma’s hives drug candidate has hit its primary endpoint, emboldening the biotech to start a phase 2b/3 trial.
Nick Paul Taylor
Sep 21, 2026 4:50am
Cue lines up new CMO and research head—Chutes & Ladders
Jul 17, 2026 8:30am
Biopharma veteran takes her CEO Cue—Chutes & Ladders
May 8, 2026 8:30am
Bayer radiology head takes top U.S. pharma spot—Chutes & Ladders
Apr 3, 2026 8:30am
GSK chief steps down in stunning move—Chutes & Ladders
Oct 3, 2025 8:30am
Boehringer lines up B-cell depletion autoimmune R&D via Cue deal
Apr 15, 2025 4:45am